Guidelines for the use of bone metabolic markers in the diagnosis and treatment of osteoporosis (2012 edition)

Journal of Bone and Mineral Metabolism

Volumn 31, Issue 1, 2013, Pages 1-15

  Nishizawa, Yoshiki ^a   Ohta, Hiroaki ^b   Miura, Masakazu ^c   Inaba, Masaaki ^d   Ichimura, Schoichi ^e   Shiraki, Masataka ^f   Takada, Junichi ^g   Chaki, Osamu ^h   Hagino, Hiroshi ⁱ   Fujiwara, Saeko ^j   Fukunaga, Masao ^k   Miki, Takami ^d   Yoshimura, Noriko ^l  

^a Osaka City University   (Japan)

^b INTERNATIONAL UNIVERSITY OF HEALTH AND WELFARE   (Japan)

^c HOKURIKU UNIVERSITY   (Japan)

^d OSAKA CITY UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^e KYORIN UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^f RESEARCH INSTITUTE AND PRACTICE FOR INVOLUTIONAL DISEASES   (Japan)

^g SAPPORO MEDICAL UNIVERSITY   (Japan)

^h YOKOHAMA ROSAI HOSPITAL   (Japan)

ⁱ TOTTORI UNIVERSITY   (Japan)

^j Health Management and Promotion Center   (Japan)

^k KAWASAKI MEDICAL SCHOOL   (Japan)

^l UNIVERSITY OF TOKYO   (Japan)

more..

Author keywords

Bone metabolic marker; Guideline; Osteoporosis

Indexed keywords

ACID PHOSPHATASE TARTRATE RESISTANT ISOENZYME; ALENDRONIC ACID; ALKALINE PHOSPHATASE; ALKALINE PHOSPHATASE BONE ISOENZYME; AMINO TERMINAL TELOPEPTIDE; BIOLOGICAL MARKER; BISPHOSPHONIC ACID DERIVATIVE; BONE SIALOPROTEIN; CARBOXY TERMINAL TELOPEPTIDE; COLECALCIFEROL; COLLAGEN TYPE 1; DEOXYPYRIDINOLINE; DEOXYPYRIDOXINE; ELDECALCITOL; ESTROGEN; HOMOCYSTEINE; OSTEOCALCIN; OSTEOPONTIN; PARATHYROID HORMONE[1-34]; PENTOSIDINE; PROCOLLAGEN LYSINE 2 OXOGLUTARATE 5 DIOXYGENASE; PROTEIN LYSINE 6 OXIDASE; SELECTIVE ESTROGEN RECEPTOR MODULATOR; TARTRATE RESISTANT ACID PHOSPHATASE 5B; UNCLASSIFIED DRUG;

ABNORMAL VALUE; ANALYTICAL PARAMETERS; ARTICLE; BONE DENSITOMETRY; BONE DENSITY; BONE MASS; BONE METABOLISM ELISA KIT; BONE TURNOVER; CLINICAL ASSESSMENT TOOL; DRUG EFFICACY; DUAL ENERGY X RAY ABSORPTIOMETRY; FRACTURE RISK; HIGH RISK POPULATION; HUMAN; IMMUNOASSAY; MOLECULAR PATHOLOGY; OSSIFICATION; OSTEOLYSIS; OSTEOPOROSIS; PATIENT SELECTION; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN CROSS LINKING; PROTEIN FUNCTION; REFERENCE VALUE; RISK; RISK ASSESSMENT; VITAMIN K DEFICIENCY;

BIOLOGICAL MARKERS; FEMALE; HUMANS; JAPAN; MALE; OSTEOPOROSIS; PRACTICE GUIDELINES AS TOPIC; SOCIETIES, MEDICAL;

EID: 84876298408     PISSN: 09148779     EISSN: 14355604     Source Type: Journal    
DOI: 10.1007/s00774-012-0392-y     Document Type: Article

References (57)

1. Braithwaite RS, Col NF, Wong JB (2003) Estimating hip fracture morbidity, mortality and costs. J Am Geriatr Soc 51:364-370
2. NIH Consensus Development Panel on Osteoporosis Prevention, Diagnosis, and Therapy (2001) Osteoporosis prevention, diagnosis, and therapy. JAMA 285:785-795
3. Blake GM, Fogelman I (2007) Role of dual-energy X-ray absorptiometry in the diagnosis and treatment of osteoporosis. J Clin Densitom 10:102-110
4. Orimo H, Hayashi Y, Fukunaga M, Sone T, Fujiwara S, Shiraki M, Kushida K, Miyamoto S, Soen S, Nishimura J, Oh-Hashi Y, Hosoi T, Gorai I, Tanaka H, Igai T, Kishimoto H, Osteoporosis Diagnostic Criteria Review Committee: Japanese Society for Bone and Mineral Research (2001) Diagnostic criteria for primary osteoporosis: year 2000 revision. J Bone Miner Metab 19:331-337
5. Kanis JA, Johnell O, Oden A, Johansson H, McCloskey E (2008) FRAX and the assessment of fracture probability in men and women from the UK. Osteoporos Int 19:385-397
6. Cummings SR, Palermo L, Browner W, Marcus R, Wallace R, Pearson J, Blackwell T, Eckert S, Black D (2000) Monitoring osteoporosis therapy with bone densitometry: misleading changes and regression to the mean. Fracture Intervention Trial Research Group. JAMA 283:1318-1321
7. Weinstein RS (2000) True strength. J Bone Miner Res 15:621-625
8. Chesnut CH III, Rosen CJ, For the Bone Quality Discussion Group (2001) Reconsidering the effects of antiresorptive therapies in reducing osteoporotic fracture. J Bone Miner Res 16:2163-2172
9. Delmas PD, Eastell R, Garnero P, Seibel MJ, Stepan J (2000) The use of biochemical markers of bone turnover in osteoporosis. Osteoporos Int 11:S2-S17
10. Nishizawa Y, Nakamura T, Ohta H, Kushida K, Gorai I, Shiraki M, Fukunaga M, Hosoi T, Miki T, Chaki O, Ichimura S, Nakatsuka K, Miura M, For the Committee on the Guidelines for the Use of Biochemical Markers of Bone Turnover in Osteoporosis, Japan Osteoporosis Society (2004) Guidelines for the use of biochemical makers of bone turnover in osteoporosis. J Bone Miner Metab 23:97-104
11. Orimo H, Hayashi Y, Fukunaga M, Sone T, Fujieara S, Schiraki M, Kushida K, Miyamoto S, Sone S, Nishimura J, Oh-hashi Y, Hosoi T, Gorai I, Tanaka H, Iga T, Kishimoto H (2001) Diagnostic criteria for primary osteoporosis: year 2000 revision. J Bone Miner Metab 19:331-337
12. Cummings SR, Karpf DB, Harris F, Harris F, Genant HK, Ensrud K, LaCroix AZ, Black DM (2002) Improvement of spine bone density and reduction in risk of vertebral fractures during treatment with antiresorptive drugs. Am J Med 112:282-289
13. Heaney RP (2003) Is the paradigm shifting? Bone 33:457-465
14. Garnero P, Hausherr E, Chapuy MC, Marcelli C, Grandjean H, Muller C, Cormier C, Breart G, Meunier PJ, Delmas PD (1996) Markers of bone resorption predict hip fracture in elderly women; EPIDOS prospective study. J Bone Mineral Res 11:1531-1538
15. Garnero P, Sornay-Rendu E, Claustrar B, Claustrat B, Delmas PD (2000) Biochemical markers of bone turnover, endogenous hormones and the risk of fracture in postmenopausal women: the OFELY study. J Bone Miner Res 15:1526-1536
16. Ross PD, Kress BC, Parson RE, Wasnich RD, Armour KA, Mizrahi IA (2000) Serum bone alkaline phosphatase and calcaneus bone density predict fractures; a prospective study. Osteoporos Int 11:76-82
17. Shiraki M, Kushida K, Fukunaga M, For the Alendronate Phase III Osteoporosis Research Group (1999) A double-masked multicenter comparative study between alendronate and alfacalcidol in Japanese patients with osteoporosis. Osteoporos Int 10:183-192
18. Morii H, Ohashi Y, Taketani Y, Fukunaga M, Nakamura T, Itabashi A, Sarkar S, Harper K (2003) Effect of raloxifene on bone mineral density and biochemical markers of bone turnover in Japanese postmenopausal women with osteoporosis: results from a randomized placebo-controlled trial. Osteoporos Int 14:793-800
19. Nishizawa Y (2011) A survey of diagnosis and treatment in Japan (in Japanese). Osteoporos Jpn 19:33-47
20. Committee of Use of Biochemical Markers of Bone Turnover in Osteoporosis, Japan Osteoporosis Society (2001) Guidelines on the use of biochemical markers of bone turnover in osteoporosis (in Japanese). Osteoporos Jpn 9:255-271
21. Committee of Use of Biochemical Markers of Bone Turnover in Osteoporosis, Japan Osteoporosis Society (2002) Guidelines on the use of biochemical markers of bone turnover in osteoporosis (in Japanese). Osteoporos Jpn 10:251-261
22. Bell KJ, Hayen A, Macaskill P, Irwig L, Craig JC, Ensrud K, Bauer DC (2009) Value of routine monitoring of bone mineral density after starting bisphosphonate treatment: secondary analysis of trial data. Br Med J 338:b2266
23. Seeman E, Delmas PD (2006) Bone quality - the material and structural basis of bone strength and fragility. N Engl J Med 354:2250-2261
24. Eriksen EF, Hodgson SF, Eastell R, Cedel SL, O'Fallon WM, Riggs BL (1990) Cancellous bone remodeling in type I (postmenopausal) osteoporosis: quantitative assessment of rates of formation, resorption, and bone loss at tissue and cellular level. J Bone Miner Res 5:311-319
25. Saito M, Marumo K (2010) Collagen-crosslinks as a determinant of bone quality: possible explanation for bone fragility in aging, osteoporosis and diabetes mellitus. Osteoporos Int 21:195-214
26. Saito M, Fujii K, Mori Y, Marumo K (2006) Role of collagen enzymatic and glycation induced cross-links as a determinant of bone quality in spontaneously diabetic WBN/Kob rats. Osteoporos Int 17:1514-1523
27. Nagaoka H, Mochida Y, Atsawasuwan P, Kaku M, Kondoh T, Yamauchi M (2008) 1,25(OH)2D3 regulates collagen quality in an osteoblastic cell culture system. Biochem Biophys Res Commun 377:674-678
28. Raposo B, Rodríguez C, Martínez-González J, Badimon L (2004) High levels of homocysteine inhibit lysyl oxidase (LOX) and down regulate LOX expression in vascular endothelial cells. Atherosclerosis 177:1-8
29. Liu G, Nellaiappan K, Kagan HM (1997) Irreversible inhibition of lysyl oxidase by homocysteine thiolactone and its selenium and oxygen analogues. Implications for homocystinuria. J Biol Chem 272:32370-32377
30. van Meurs JB, Dhonukshe-Rutten RA, Pluijim SM, van der Klift M, de Jonge R, Lindemans J, de Groot LC, Hofman A, Witteman JC, van Leeuwen JP, Breteler MM, Lips P, Pols HA, Uitterlinden AG (2004) Homocysteine levels and the risk of osteoporotic fracture. N Engl J Med 350:2033-2041
31. Shiraki M, Urano T, Kuroda T, Saito M, Tanaka S, Miyao-Koshizuka M, Inoue S (2008) The synergistic effect of bone mineral density and methylenetetrahydrofolate reductase (MTHFR) polymorphism (C677T) on fractures. J Bone Miner Metab 26:595-602
32. Amizuka N, Li M, Hara K, Kobayashi M, de Freitas PH, Ubaidus S, Oda K, Akiyama Y (2009) Warfarin administration disrupts the assembly of mineralized nodules in the osteoid. J Electron Microsc 58:55-65
33. Tsugawa N, Shiraki M, Suhara Y, Kamao M, Tanaka K, Okano T (2006) Vitamin K status of healthy Japanese women: age-related vitamin K requirement for gamma-carboxylation of osteocalcin. Am J Clin Nutr 83:380-386
34. Vergnaud P, Garnero P, Meunier PJ, Bréart G, Kamihagi K, Delmas PD (1997) Undercarboxylated osteocalcin measured with a specific immunoassay predicts hip fracture in elderly women: the EPIDOS study. J Clin Endocrinol Metab 82:719-724
35. Garnero P, Sornay-Rendu E, Claustrat B, Delmas PD (2000) Biochemical markers of bone turnover, endogenous hormones and risk of fractures in postmenopausal women: the OFELY study. J Bone Miner Res 15:1526-1536
36. Okabe R, Nakatsuka K, Inaba M, Miki T, Naka H, Masaki H, Moriguchi A, Nishizawa Y (2001) Clinical evaluation of the Elecsys beta-CrossLaps serum assay, a new assay for degradation products of type I collagen C-telopeptides. Clin Chem 47:1410-1414
37. Nishizawa Y, Inaba M, Ishii M, Yamashita H, Miki T, Goto H, Yamada S, Chaki O, Kurasawa K, Mochizuki Y (2008) Reference intervals of serum tartrate-resistant acid phosphatase type 5b activity measured with a novel assay in Japanese subjects. J Bone Miner Metab 26:265-270
38. Kress BC, Mizrahi IA, Armour KW, Marcus R, Emkey RD, Santora AC 2nd (1999) Use of bone alkaline phosphatase to monitor alendronate therapy in individual postmenopausal osteoporotic women. Clin Chem 45:1009-1017
39. Melkko J, Kauppila S, Niemi S, Risteli L, Haukipuro K, Jukkola A, Risteli J (1996) Immunoassay for intact amino-terminal propeptide of human type I procollagen. Clin Chem 42:947-954
40. Iki M, Akiba T, Matsumoto T, Nishino H, Kagamimori S, Kagawa Y, Yoneshima H, JPOS Study Group (2004) Reference database of biochemical markers of bone turnover for the Japanese female population. Japanese Population-based Osteoporosis (JPOS) Study. Osteoporos Int 15:981-991
41. Bjarnason NH, Sarker S, Duong T, Mitlak B, Delmas PD, Christiansen C (2001) Six and twelve month changes in bone turnover are related to reduction in vertebral fracture risk during 3 years of raloxifene treatment in postmenopausal osteoporosis. Osteoporos Int 12:922-930
42. Eastell R, Barton I, Hannon RA, Chines A, Garnero P, Delmas PD (2003) Relationship of early changes in bone resorption to the reduction in fracture risk with risedronate. J Bone Miner Res 18:1051-1056
43. Delmas PD, Seeman E (2004) Changes in bone mineral density explain little of the reduction in vertebral or nonvertebral fracture risk with anti-resorptive therapy. Bone 34:599-604
44. Delmas PD, Vrigens B, Eastell R, Roux C, Pols HA, Ringe JD, Grauer A, Cahall D, Watts NB (2007) Effect of monitoring bone turnover markers on persistence with risedronate treatment of postmenopausal osteoporosis. J Clin Endocrinol Metab 92:1296-1304
45. Imai E, Horio M, Watanabe T, Iseki K, Yamagata K, Hara S, Ura N, Kiyohara Y, Moriyama T, Ando Y, Fujimoto S, Konta T, Yokoyama H, Makino H, Hishida A, Matsuo S (2009) Prevalence of chronic kidney disease in the Japanese general population. Clin Exp Nephrol 13:621-630
46. Yamada S, Inaba M, Kurajoh M, Shidara K, Imanishi Y, Ishimura E, Nishizawa Y (2008) Utility of serum tartrate-resistant acid phosphatase (TRACP5b) as a bone resorption marker in patients with chronic kidney disease: independence from renal dysfunction. Clin Endocrinol (Oxf) 69:189-196
47. Inaba M, Kurajoh M, Okuno S, Imanishi Y, Yamada S, Mori K, Ishimura E, Yamakawa T, Nishizawa Y (2010) Poor muscle quality rather than reduced lean body mass is responsible for the lower serum creatinine level in hemodialysis patients with diabetes mellitus. Clin Nephrol 74:266-272
48. Delmas PD, Vrijens B, Eastell R, Roux C, Pols HA, Ringe JD, Grauer A, Cahall D, Watts NB (2003) A reinforcement message based on bone turnover marker response influences long-term persistence with risedronate in osteoporosis: IMPACT study. J Bone Miner Res 18:S374
49. Kurasawa K, Chaki O, Hirahara F (2006) Evaluation of serum bone-specific alkaline phosphatase using automated chemiluminescent enzyme immunoassay (in Japanese). Jpn J Med Pharm Sci 55:279-285
50. Shiraki M, Aoki C, Yamazaki N, Ito Y, Tsugawa N, Sunahara Y, Okano T (2007) Clinical assessment of undercarboxylated osteocalcin measurement in serum using and electrochemiluminescence immunoassay: establishment of cut-off values to determine vitamin K insufficiency in bone and to predict fracture leading to clinical use of vitamin K2 (in Japanese). Jpn J Med Pharm Sci 57:537-546
51. Nishizawa Y, Inaba M, Ishi K, Yamashita H, Miki T, Goto H, Yamada S, Chaki O, Karasawa K (2005) Evaluation of newly developed kit for measurement of bone-specific tartrate-resistant acid phosphates in blood (in Japanese). Jpn J Med Pharm Sci 54:709-717
52. Sone T, Yoshikawa K, Tamada T, Takeda N, Fukunaga M (2001) Clinical application of radioimmunoassay for determination of serum intact PINP (procollagen type I amino-terminal propeptide) (in Japanese). Clin Endocrinol 49:1133-1138
53. Greenspan SL, Parker RA, Ferguson L, Rosen HN, Maitland-Ramsey L, Karpf DB (1998) Early changes in biochemical markers of bone turnover predict the long-term response to alendronate therapy in representative elderly women: a randomized clinical trial. J Bone Miner Res 13:1431-1438
54. Miyauchi A, Matsumoto T, Sugimoto T, Tsujimoto M, Warner MR, Nakamura T (2010) Effects of teriparatide on bone mineral density and bone turnover markers in Japanese subjects with osteoporosis at high risk of fracture in a 24-month clinical study: 12-months, randomized, placebo-controlled, double-blind and 12-month open-label phases. Bone 47:493-502
55. Tsujimoto M, Chen P, Miyauchi A, Sowa H, Krege JH (2011) PINP as an aid for monitoring patients treated with teriparatide. Bone 8:798-803
56. Nakamura T, Matsumoto T, Sugimoto T, Shiraki M (2011) Effect of weekly teriparatide in patients with osteoporosis. J Bone Miner Res 26:S1201
57. Eastell R, Brainbridge PR (2003) Bone turnover markers: their place in the investigation of osteoporosis. In: Orwoll ES, Bliziotes M (eds) Osteoporosis: pathophysiology and clinical management. Humana Press, Totowa, pp 185-197